AlphAIAlphAI — Financial news for AI agents
stocktitan.netNOV 32 min read$CMPS

An extra dose extended a depression treatment’s effect to one year in trial data.

Compass Pathways (CMPS) is nearing completion of its NDA submission for COMP360, a treatment for treatment-resistant depression (TRD), with a filing expected in two weeks. Positive Phase 3 trial data shows durability of effect up to one year. The company aims for a H1 2027 launch, subject to FDA approval. COMP360 is seen as a potential blockbuster with a large market opportunity. Compass also has a late-stage PTSD trial ongoing and a strong cash position into 2028.

Original reporting
stocktitan.net
Published Nov 3, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 11:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$CMPS
Bullish
high confidence
Mentioned
$CMPS
Relevance
8/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CMPSBullishMed
01

Why it matters

The disclosed 52‑week open‑label data and imminent NDA filing represent the first public confirmation of durability and regulatory progress, likely to move the stock.

02

Market read

First disclosure of pivotal trial results and NDA filing for a potential blockbuster psychedelic therapy, a material catalyst for CMPS.

03

What to watch

Potential competition from other psychedelic programs and reimbursement uncertainties.

Relevance 8/10Novelty 9/10Timing: today

Background

Compass Pathways is a London‑based biotech developing synthetic psilocybin (COMP360) for treatment‑resistant depression and PTSD, holding Breakthrough Therapy designation.

Company-level read

Ticker impact

$CMPSBullishHigh confidence
Context

Compass Pathways announced positive Phase 3 trial data extending COMP360 durability to one year and a near‑term NDA filing, a first‑time disclosure of pivotal results.

Expected impact

likely upward pressure as market prices in expected FDA approval and revenue potential

Evidence & confidence

Phase 3 data and NDA filing are primary, material events for a biotech; historically such news drives significant price moves.

Market effects

Sector

May boost sentiment for the broader psychedelic‑therapy and mental‑health biotech sector.

Regional

Positive for UK‑listed biotech exposure and US mental‑health investors.

Global

Highlights growing interest in novel psychiatric treatments worldwide.

Counterpoint

What could challenge this read

Regulatory hurdles or safety concerns could delay approval, limiting upside.

Key entities

  • company
    Compass Pathways plc

    Biotech developing COMP360 for TRD and PTSD.

  • executive
    Kabir Nath

    CEO of Compass Pathways, quoted on trial progress.

Read at source← All news

Related articles

OCT 26
$CMPSMed

B.Riley reiterates Buy on Compass Pathways stock, $22 target

B.Riley reiterated a Buy rating and $22 target on Compass Pathways (CMPS) after the VA selected sites for psychedelic deployment. CMPS is up 78% over the past year and 62% YTD, trading at $11.15. The company's COMP360 therapy could begin dosing soon, with FDA approval possible within 3-6 months. B.Riley estimates significant revenue potential from VA patients. Analysts highlight positive trial data and strong financial position.

investing.com2 min
OCT 24
$CMPSHighAI 9/10

Tovecimig Plus Paclitaxel Improves ORR vs Paclitaxel Alone in Biliary Tract Cancer

Tovecimig (CTX-009) plus paclitaxel showed improved objective response rates (18.0% vs 5.3%) over paclitaxel alone in advanced biliary tract cancer, meeting the primary endpoint of the phase 2/3 COMPANION-002 trial. Median PFS was 4.7 months vs 2.6 months, but OS was similar (8.9 vs 9.4 months). The trial involved 168 patients and was presented at the 2026 ESMO Congress. According to Compass Therapeutics, the combination represents a promising new strategy for biliary tract cancer.

onclive.com3 min
OCT 16
$CMPSMedAI 8/10

Can Durable Response to Psilocybin Reshape Treatment-Resistant Depression Care?

Compass Pathways presented real-world analyses showing that treatment-resistant depression (TRD) has significant economic burden during treatment-resistant episodes, with costs declining as patients stabilize. Their psilocybin formulation, COMP360, showed sustained clinical benefit in phase 3 trials, with 25% and 39% of participants achieving meaningful symptom reduction in COMP005 and COMP006, respectively, maintained through week 26.

psychiatrictimes.com3 min
SEP 17
$DFTXMed

DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push?

Definium Therapeutics (DFTX) and Compass Pathways (CMPS) are in focus due to a White House push to accelerate psychedelic therapy research. Both companies are developing late-stage psychedelic therapies for psychiatric conditions. DFTX has a 62% upside with a $36.67 price target, while CMPS has a 227% upside with a $21.75 target. Both companies welcomed the executive order and highlighted their ongoing clinical trials.

stocktwits.com2 min